Hamilton company that makes cancer drugs will have 10 times the space
Published March 1, 2023 at 11:23 am
Hamilton-based AtomVie Global Radiopharma Inc., which is an emerging distributor of radiotherapeutics — an innovative class of drugs used to treat cancer patients — is moving into a new space that could increase its capacity by a factor of 10.
Atomvie announced today (March 1) that it will be leasing a 64,000-sq.-ft. facility with Panattoni Development Company at 10 Aeropark Blvd. — convenient to both Hamilton John C. Munro airport, Pearson Airport in Mississauga, and the United States border. Currently, Atomvie is located at McMaster University, where it produces cancer drugs for more than 10 international radiopharmaceutical GMP manufacturing programs. Those goods are difficult to make in many parts of the world, so Atomvie handles production and ships to partners in some 17 nations across Asia, Australia, Europe, and the United States.
The new facility, which is expected to include cleanrooms and laboratories to sustain over 18 production lines and space for dedicated, high-volume commercial manufacturing, a media release from Atomvie stated. There will also be more room for storage, packaging, and shipping.
“(This) buildout that will increase our capacity more than 10-fold,” Atomvie CEO Bruno Paquin says. “We are thrilled to continue being part of the Hamilton radiopharmaceutical ecosystem and by partnering with Panattoni, we were able to choose our new facility’s home to meet clinical and commercial supply needs for radiotherapeutics, resulting in patients receiving much-needed therapies.”
AtomVie, officially launched last August after successfully obtaining $40 million in series A financing by Avego, a New York-based investment firm. It was spawned by building on expertise developed at the Centre for Probe Development and Commercialization, which is a centre of excellence at McMaster.
(Cover image: Panattoni Development Company; CNW Group; AtomVie Global Radiopharma Inc.)